Zhitong Finance App News, Clover Bio-B (02197.HK) announced positive preliminary data from a phase II clinical trial conducted in the elderly population in Australia. The test was used to evaluate SCB1022 (rSV+hMPv) and SCB-1033 (rSV+hMPv+pIV3) protein vaccine candidates. The antigen is a trimeric subunit vaccine antigen based on stabilized F protein (PrEF) before fusion, using Trimer-Tag (protein trimer) vaccine development platform validated by Clover Biology.
智通財經·09/07/2026 00:17:10
語音播報
Zhitong Finance App News, Clover Bio-B (02197.HK) announced positive preliminary data from a phase II clinical trial conducted in the elderly population in Australia. The test was used to evaluate SCB1022 (rSV+hMPv) and SCB-1033 (rSV+hMPv+pIV3) protein vaccine candidates. The antigen is a trimeric subunit vaccine antigen based on stabilized F protein (PrEF) before fusion, using Trimer-Tag (protein trimer) vaccine development platform validated by Clover Biology.